Alveolar Type II Epithelial Cells Contribute to the Anti-Influenza A Virus Response in the Lung by Integrating Pathogen- and Microenvironment-Derived Signals

S. Stegemann-Koniszewski, Andreas Jeron, Marcus Gereke, Robert Geffers, Andrea Kröger, Matthias Gunzer, Dunja Bruder

Influenza A virus (IAV) periodically causes substantial morbidity and mortality in the human population. In order to confront the health hazard posed by IAV, we need to complete our understanding of its pathogenesis. In the lower respiratory tract, the lining epithelium is comprised of alveolar type I and type II epithelial cells (AECI and AECII), which are increasingly recognized for their immunological potential. So far, little is known about their reaction to IAV and their contribution to respiratory antiviral immunity in vivo. Therefore, we characterized the AECII response during early IAV infection by analyzing transcriptional regulation in cells sorted from the lungs of infected mice. We detected rapid and extensive regulation of gene expression in AECII following in vivo IAV infection. The comparison to transcriptional regulation in lung tissue revealed a strong contribution of AECII to the respiratory response. IAV infection triggered the expression of a plethora of antiviral factors and immune mediators in AECII with a high prevalence for interferon-stimulated genes. Functional pathway analyses revealed high activity in pathogen recognition, immune cell recruitment, and antigen presentation. Ultimately, our analyses of transcriptional regulation in AECII and lung tissue as well as interferon I/III levels and cell recruitment indicated AECII to integrate signals provided by direct pathogen recognition and surrounding cells. Ex vivo analysis of AECII proved a powerful tool to increase our understanding of their role in respiratory immune responses, and our results clearly show that AECII need to be considered a part of the surveillance and effector system of the lower respiratory tract.

ABSTRACT  Influenza A virus (IAV) periodically causes substantial morbidity and mortality in the human population. In the lower lung, the primary targets for IAV replication are type II alveolar epithelial cells (AECII), which are increasingly recognized for their immunological potential. So far, little is known about their reaction to IAV and their contribution to respiratory antiviral immunity in vivo. Therefore, we characterized the AECII response during early IAV infection by analyzing transcriptional regulation in cells sorted from the lungs of infected mice. We detected rapid and extensive regulation of gene expression in AECII following in vivo IAV infection. The comparison to transcriptional regulation in lung tissue revealed a strong contribution of AECII to the respiratory response. IAV infection triggered the expression of a plethora of antiviral factors and immune mediators in AECII with a high prevalence for interferon-stimulated genes. Functional pathway analyses revealed high activity in pathogen recognition, immune cell recruitment, and antigen presentation. Ultimately, our analyses of transcriptional regulation in AECII and lung tissue as well as interferon I/III levels and cell recruitment indicate AECII to integrate signals provided by direct pathogen recognition and surrounding cells. Ex vivo analysis of AECII proved a powerful tool to increase our understanding of their role in respiratory immune responses, and our results clearly show that AECII need to be considered a part of the surveillance and effector system of the lower respiratory tract.

IMPORTANCE  In order to confront the health hazard posed by IAV, we need to complete our understanding of its pathogenesis. AECII are primary targets for IAV replication in the lung, and while we are beginning to understand their importance for respiratory immunity, the in vivo AECII response during IAV infection has not been analyzed. In contrast to studies addressing the response of AECII infected with IAV ex vivo, we have performed detailed gene transcriptional profiling of AECII isolated from the lungs of infected mice. Thereby, we have identified an exceptionally rapid and versatile response to IAV infection that is shaped by pathogen-derived as well as microenvironment-derived signals and aims at the induction of antiviral measures and the recruitment and activation of immune cells. In conclusion, our study presents AECII as active players in antiviral defense in vivo that need to be considered part of the sentinel and effector immune system of the lung.

Influenza A virus (IAV) still poses a serious threat to human health, and a detailed understanding of IAV pathogenesis is essential to adequately confront this hazard. IAV infections are primarily restricted to the respiratory tract, where epithelial cells, alveolar macrophages (AM), and dendritic cells (DC) trigger the first innate responses (1). IAV bears ligands for several pathogen recognition receptors (PRR), and the main triggered PRR are Toll-like receptor 3 (TLR3) and TLR7 as well as RIG-I, MDA5, and the NLRP3 inflammasome (1). These are engaged in the antiviral response in a cell-type-specific manner (2, 3). Via partly redundant signaling pathways, PRR ligation leads to the activation of effector mechanisms comprised of type I/III interferons (IFNs), inflammatory mediators, antimicrobial effectors, and signals inducing adaptive immunity. In general, viral infections are marked by the strong release of type I interferons. These trigger the expression of a multitude of interferon-stimulated genes (ISG) through the ubiquitously expressed IFN-α/β receptor (IFNAR) (2). ISG expression is also induced through IFN-λ (IFN III), which is released during IAV infection and is sensed through the interleukin-28 (IL-28) receptor α (IL-28Rα) primarily expressed by epithelial cells of the respiratory tract and gut (4).

In the lower respiratory tract, the lining epithelium is comprised of alveolar type I and type II epithelial cells (AECI and AECII, respectively), and at this site, AECII are the main target...
cells for IAV replication (5, 6). AECII cover about 5% of the alveolar surface, while they comprise about 60% of the alveolar lining cells and 15% of the parenchymal cells (7). Until recently, the secretion of surfactant, the maintenance of the mechanical barrier, and the provision of constitutive antimicrobial defense were conceived as their main functions (7, 8). Beyond these, we are only beginning to understand the potential of AECII to regulate respiratory immune responses in autoimmunity and infection (9–12).

Since AECII are primary targets for viral replication in the lower lung and actively contribute to pulmonary immunity, it is likely that they influence efficient host responses directed at IAV. A number of studies have addressed the response of AECII to IAV in vitro and showed them to express functional PRR and to produce cytokines and chemokines (13–17). The nature and the relevance of the AECII response to IAV, however, lack ultimate clarification, as these studies were performed using cell lines or primary cells infected in culture. Little is known about the AECII response to IAV infection in vivo and how this contributes to the respiratory immune reaction. To overcome these limitations, we characterized the in vivo response of AECII to IAV infection by analyzing primary AECII from the lungs of infected mice.

RESULTS

IAV infection triggers AECII-specific transcriptional regulation in vivo. We have previously optimized our IAV infection model for the isolation of pure and viable AECII that express increasing amounts of viral protein over the first days of infection (9, 18). In this model of lethal IAV infection, mice rapidly lose weight, the virus replicates efficiently in the lungs, and high copy numbers of the viral genome are detected in the isolated AECII (see Fig. S1 in the supplemental material). Typically, inflammatory mediators and immune cell recruitment to the respiratory tract are induced by day 3 postinfection (19), and we analyzed transcriptional regulation in AECII and lung tissue at this time point. For AECII, two independent microarray experiments were conducted for each condition and the material for each independent experiment was pooled from five infected animals. For lung tissue, three independent microarrays were performed for each condition and each array represents an independent animal. Fold change (FC) values of 2 or more over controls were considered indicative of up- or downregulation. In lung tissue, 878 transcripts were upregulated and 123 were downregulated following IAV infection. Extensive transcriptional regulation was also detected in AECII, with 546 upregulated and 42 downregulated transcripts (Fig. 1A). In the lung, the 5 most intensely upregulated transcripts were interleukin-6 (IL-6) (FC $\geq 2$), CXCL10, and the IFN-induced proteins Mx1 and Rsad2 as well as Slfn4, which has been suggested to be IFN I inducible (20). There was an overlap with AECII, where Rsad2 and Slfn4, along with the IFN-induced proteins Ifit1, Ifit3, and Iigp1, were among the top 5 most regulated transcripts, indicating a prominent role for IFNs in the AECII response (Fig. 1B). The intense upregulation of CXCL5, CXCL9, and CXCL10 (Fig. 1B) in AECII as well as the large overlap of the transcripts found regulated in either lungs or AECII (Fig. 1C) pointed at a strong potential of AECII to contribute to respiratory immunity. In order to confirm the AECII transcriptional regulation following in vivo IAV infection detected by the microarray analyses, the expression of a selection of these transcripts was an-
alyzed by quantitative real-time PCR. Indeed, this approach confirmed the significant upregulation of CXCL5, CXCL10, IFIT2, IRF7, MX2, and USP18 (see Fig. S2). Overall, the detection of AECII-specific transcripts showed that AECII most likely serve cell-type-specific functions. These transcripts were associated with Gene Ontology (GO) terms such as defense response (Bonferroni corrected $P$ value, $2.8 \times 10^{-12}$), innate immune response (corrected $P$ value, 0.00013), and cytokine production (corrected $P$ value, 0.00077). The quality, i.e., whether up- or downregulation occurred, of transcriptional regulation in AECII and lung tissue was not changed between the two sample sets (Fig. 1D). Overall, these results clearly demonstrated that AECII strongly react to IAV infection in vivo and hold strong potential to contribute to the respiratory immune response. To characterize this contribution in greater detail, we performed AECII transcriptional analyses over the early course of infection.

**Early transcriptional regulation in AECII follows distinct kinetics.** Over the first 3 days postinfection, the number of transcripts differentially regulated in AECII strongly increased and the number of downregulated transcripts was considerably lower than the number of those upregulated. This suggested that AECII were increasingly stimulated over time and that activation rather than suppression of gene transcription dictated their response (Fig. 2A). k-means clustering was performed (Fig. 2B to D), and the resulting clusters included transcripts upregulated exclusively on day 1, 2, or 3 and transcripts downregulated over time. Most differentially expressed transcripts were upregulated on day 3 postinfection, and these further segregated into transcripts (i) slightly upregulated on day 1, (ii) slightly upregulated on days 1 and 2, and (iii) slightly upregulated from day 2 onward (Fig. 2C and D). As IAV infection induces the rapid release of IFN I/III, we assessed the prevalence of ISG within the clusters using the Interactome v2.01 database (21). By far, the highest proportion of ISG was present in clusters 6 and 7, pointing at a strong and progressive AECII response to IFN I and/or IFN III (Fig. 2E).

**TLR7 deficiency alters the regulation of gene expression in AECII.** We hypothesized that the host relies on IAV-sensing PRR to mount a full AECII response and analyzed transcriptional regulation in lungs and AECII of TLR7-knockout (TLR7ko) mice. On day 3 post-IAV infection, considerable transcriptional regulation was detected (see Fig. S3 in the supplemental material). Over time, AECII were increasingly activated also in TLR7ko mice (Fig. 3A). However, the number of upregulated transcripts was clearly reduced in comparison to wild-type (WT) AECII (Fig. 3B), whereas the comparison of gene transcription levels in AECII isolated from uninfected WT and TLR7ko mice did not yield differences in baseline expression (see Fig. S3 in the supplemental material). As there was a large overlap with the transcripts regulated in the WT, TLR7ko AECII did not harbor an independent gene expression profile (Fig. 3C). The 90 transcripts exclusively regulated in TLR7ko AECII were not significantly associated with any annotated Gene Ontology (GO) terms, whereas the transcripts regulated only in WT AECII showed significant association with GO terms such as innate immune response (Bonferroni corrected $P$ value, $2.68 \times 10^{-21}$), immune effector process (1.38 $\times 10^{-18}$), and defense response to virus ($2.28 \times 10^{-15}$). A list of the most intensely regulated of these TLR7-dependent transcripts is provided in Table S1 in the supplemental material. In addition, the fold changes of the vast majority of the transcripts upregulated in both mouse strains were lower in TLR7ko AECII throughout the early course of infection (Fig. 3D). Therefore, the AECII response of TLR7-deficient hosts during IAV infection was blunted regarding both the number of differentially expressed transcripts and the degree of fold change regulation, demonstrating the importance of a single PRR for the full AECII response.

**IAV infection triggers transcriptional regulation of a multitude of immunological factors.** We performed pathway analyses on the transcripts differentially expressed in AECII on day 3 post-IAV infection using Ingenuity pathway analysis (IPA). The most significantly overrepresented pathways clearly indicated strong immunological activity, as they were involved in pathogen recognition, the induction and shaping of immune responses, and immune cell recruitment (Table 1). Increasing $P$ values over time illustrated increasing relevance in the AECII response. These results clearly demonstrated that AECII exert pronounced immunological functions in IAV infection in vivo. Of note, the functional pathways overrepresented in the transcripts regulated in TLR7ko AECII were largely identical to those identified for WT AECII (see Table S2 in the supplemental material).

We furthermore evaluated transcriptional regulation of key antiviral and immunological factors within the transcript differentially regulated in AECII. Transcription of several, mainly nucleic acid-sensing PRR was upregulated in AECII in the course of IAV infection (Fig. 4A). Fold change regulation in AECII peaked on day 3 and was similar to or even higher than that detected for whole-lung tissue.

IFIT (IFN-induced protein with tetratricopeptide repeats) 1 to 3, all of which contribute to antiviral defense (22), showed exceptionally strong induction in AECII (Fig. 4B) that by far exceeded that in lung tissue. Interestingly, out of the genes coding for IFN I and IFN III only Ifnb1 was differentially upregulated in AECII (Fig. 4B). In contrast, also the transcription of interferon regulatory factor 7 (IRF7), which induces IFN and ISG expression (1), was extensively regulated in WT AECII (Fig. 4B).

Also, the transcription of chemokines and cytokines was efficiently induced in AECII, underlining their immunological potential in respiratory infection (Fig. 4C). The extent of upregulation increased over time, and for most cytokines, upregulation was more pronounced in lungs than in AECII. Of note, however, transcription of Cxcl5, Cxcl9, and Cxcl10 was upregulated more than 25-fold in AECII and Cxcl5 and Ccl5 upregulation in AECII exceeded that in lung tissue.

Next to the secretion of immunological mediators, AECII are capable of presenting antigen on major histocompatibility complex class I (MHC-I) and MHC-II molecules as well as providing costimulation (10, 23–25). Indeed, antigen presentation was among the most significantly enriched pathways in the transcripts differentially expressed in AECII, and the transcriptional regulator of the MHC-I complex NLRC5 (NOD-like receptor family CARD domain-containing 5) as well as Ttap1 (transporter associated with antigen processing 1) was upregulated in AECII to a larger extent than in lung tissue (Fig. 4D). Additionally, we detected the upregulation of CD86 as well as H2-DMb2 in AECII following IAV infection.

For the selected factors, transcriptional regulation in TLR7ko AECII showed similar kinetics but in the majority of cases did not reach the magnitude of upregulation observed in WT AECII (see Fig. S4 in the supplemental material). Taken together, AECII reacted to respiratory IAV infection by the differential expression of...
Kinetics of transcriptional regulation in WT AECII in the early course of IAV infection. Mice were infected with IAV and sacrificed 1, 2, or 3 days later. RNA from sorted AECII (n = 2 individual samples for each condition; 5 mice per sample) was subjected to microarray analysis. For each time point, microarray data were compared to the uninfected control. (A) The number of transcripts up-/downregulated with a fold change of ≥2 in AECII. (B) k-means cluster analysis of the transcripts differentially regulated with a fold change of ≥2 in AECII on day 1, 2, or 3. Data were transformed into Z scores. Line plots show the (Continued)
a multitude of molecules involved in the induction and shaping of immune responses, demonstrating their exceptionally high potential to contribute to respiratory immunity in vivo.

**AECII transcriptional regulation correlates with PMN recruitment and IFN I/III levels.** AECII most likely take part in the recruitment of immune effector cells to the respiratory tract. We determined the overall cellularity of bronchoalveolar lavage (BAL) fluid, and a strong and significant increase in cell numbers was detected on day 3 postinfection (Fig. 5A). Since the majority of the chemokines differentially expressed in AECII act as chemoattractants for macrophages and other myeloid cells, mainly polymorphonuclear neutrophils (PMN), we determined the macrophage and PMN populations. In uninfected mice, macrophages were the main cell type present and their relative contribution was significantly reduced by day 3 (Fig. 5B). At the same time, there was a significant increase in the PMN population size and the absolute PMN number (Fig. 5B and C). The kinetics of PMN recruitment and AECII transcriptional regulation of chemokines suggest that AECII contribute to the attraction of innate effectors to the lung. Of note, the blunted transcriptional regulation of chemokines in TLR7-deficient hosts was in line with a delayed recruitment of PMN (see Fig. S5 in the supplemental material).

In order to link ISG induction to interferon levels in the lung, we assessed the levels of bioactive IFN I/III in BAL fluid. A substantial increase in IFN I/III activity was detected on day 2 post-IAV infection, with a significant increase by day 3 (Fig. 5C) which directly correlated with the massive induction of ISG in AECII by day 3 postinfection. Of note, IFN I/III levels were significantly reduced in TLR7-deficient mice (see Fig. S5 in the supplemental material). Taken together, these findings imply a critical role for IFN I/III for the AECII response following IAV infection.

Figure Legend Continued

Z scores of the transcripts of the individual k-means clusters over time (for both replicates per time point). The blue lines indicate the average Z score. (C) Heat map visualization of the Z scores in the individual k-means clusters. The number of transcripts and selected members are indicated for each cluster. (D) Heat map visualization of the average Z score value per column of the k-means clusters. (E) Percent interferon response genes within the individual k-means clusters as determined using the Interferome v2.01 database.
Stegemann-Koniszewski et al.

**DISCUSSION**

Nearly all of the research that has addressed the response of AECII to IAV was performed in cells infected with the virus ex vivo (13–17), whereas in vivo studies mostly did not differentiate between different cell types of the epithelium (26).

Our analyses revealed that AECII strongly react to respiratory IAV infection in vivo. The response was exceptionally versatile and included differential expression of a plethora of factors associated with antiviral activity and the induction of immune responses. Several antiviral proteins were among the most intensely upregulated transcripts, and the importance of their epithelial expression was highlighted by the finding that fold change induction in AECII often exceeded that in lung tissue. Deficiency in IFITM3, which was upregulated 12-fold in AECII and only 2-fold in lung tissue on day 3 (data not shown), leads to enhanced viral titers and increased mortality in mice, and patients with IFITM3 mutations exhibit compromised IAV restriction (27). Also, ISG15 and Gbp3 (guanylate-binding protein 3) contribute specifically to the antiviral host defense (28, 29). Out of the genes encoding IFN I/III, only Ifnb1 was upregulated in AECII following in vivo IAV infection. This was surprising at first, especially as AECII are described to depend on TLR7 (33).

It has been shown that during in vivo IAV infection IFN-β is predominantly produced not by the epithelium but by CD11c-expressing cell populations (31). Furthermore, the depletion of plasmacytoid dendritic cells (pDC) was reported to lead to a significantly diminished IFN I production in the lungs of IAV-infected mice (32). Therefore, we believe that also in our model resident and newly recruited pDC are most likely the main producers of IFN I. This is well in line with the significantly decreased IFN I/III production in TLR7ko mice, as pDC are known to contribute specifically to the antiviral host defense (28, 29).

Extensive transcriptional regulation of CXCL5, CXCL9, and CXCL10 demonstrated how broadly AECII act on pulmonary host defense. Even though upregulation of most cytokines in lung tissue exceeded that in AECII, upregulation of CXCL5 and CCL5 in AECII was stronger than in lung tissue. Blocking of CCL5 in respiratory viral infection reduces the recruitment of CD4+ and CD8+ T cells (34), and AECII are the predominant source of CXCL5 in the lungs of mice treated with lipopolysaccharide (35).

Regarding the role of AECII in the recruitment of effector cells, the significantly attenuated PMN recruitment in TLR7ko mice was well in line with the alleviated induction of CXCL5 expression in their AECII. Of note, however, this reduction in PMN recruitment is not necessarily a consequence of the reduced production of chemotactic cytokines only by AECII, as their upregulation was also strongly reduced in whole-lung tissue of TLR7ko mice. Nevertheless, the extensive induction of cytokine and chemokine transcription in AECII pointed at a strong contribution of AECII to the overall lung response to infection in vivo.

Next to MHC-I antigen presentation in AECII, there was also evidence for MHC-II presentation and costimulation. In fact, lethal IAV infection induces MHC-II expression on lung epithelial cells (23), and AECII have been observed to present antigen to CD4+ T cells in the context of mycobacterial infection (25). Furthermore, we have previously shown that AECII efficiently present antigen to and activate CD4+ T cells and that they are able to promote the induction of regulatory T cells (10). Therefore, MHC-I and also MHC-II antigen presentation displays strategies for AECII to shape the lower respiratory tract immune response during IAV infection in vivo.

A clear and distinct role for TLR7 in survival following IAV infection has so far been demonstrated only in mice expressing functional Mx1, unlike the commonly used laboratory mouse strains (36). We and others have rather found TLR7 to be involved in the fine-tuning of innate and adaptive anti-IAV responses (19, 37, 38), and in our model of respiratory IAV infection, there was no difference in morbidity and mortality between WT and TLR7-deficient hosts (see Fig. S6 in the supplemental material). Nevertheless, we found the AECII response to IAV to be substantially blunted in the absence of TLR7. As both unchanged and clearly diminished IFN I production have been described in TLR7ko mice (19, 39), it was surprising that TLR7 played such a central role in ensuring a robust early IFN response in our model. Most likely, the reduced levels of IFN I/III in the respiratory tract of TLR7ko mice to a large extent accounted for the blunted AECII response in these mice, especially since many of the regulated transcripts were ISG. Of note, the numbers of AECII isolated from WT and TLR7ko animals were similar (see Fig. S6 in the supplemental material). However, TLR7ko mice displayed a reduction in viral load in lung tissue and the isolated AECII (see Fig. S6 in the supplemental material). IAV has previously been described to depend on TLR7 for efficient replication (39), and this reduction in viral load, even though not significant by day 3, was a likely reason for the blunted IFN I/III and in turn the blunted AECII response in TLR7ko mice. We are not able to dissect the interdependence of viral replication, IFN I/III production, and transcriptional regulation in AECII from our data. Silencing of TLR7 and other IAV

**TABLE 1** Functional pathways most significantly overrepresented in the transcripts differentially expressed in AECII

| Ranking by P value | Canonical pathway | AECII day 1 | AECII day 2 | AECII day 3 |
|--------------------|------------------|------------|------------|------------|
| 1                  | Communication between innate and adaptive immune cells | 1.53       | 2.05       | 20.49      |
| 2                  | Role of pattern recognition receptors in recognition of bacteria and viruses | 3.03       | 19.04      |            |
| 3                  | Granulocyte adhesion and diapedesis | 2.53       | 3.31       | 15.44      |
| 4                  | Cross talk between dendritic cells and natural killer cells |            | 14.79      |            |
| 5                  | Dendritic cell maturation |            | 14.33      |            |
| 6                  | TREM1 signaling | 1.73       | 2.42       | 13.79      |
| 7                  | Agranulocyte adhesion and diapedesis | 2.44       | 3.14       | 12.91      |
| 8                  | Altered T cell and B cell signaling in rheumatoid arthritis |            |            | 12.79      |
| 9                  | Interferon signaling |            | 4.56       | 12.64      |
| 10                 | Antigen presentation pathway | 2.34       |            | 11.66      |

*The 10 pathways most significantly overrepresented in the transcripts differentially regulated in WT AECII on day 3 postinfection are listed. Pathways were ranked by Fisher exact test P value. The data columns indicate the −log(P value) for overrepresentation of the respective pathways for all microarray data sets (WT AECII; days 1, 2, and 3 postinfection), listing only those values indicating statistical significance (P < 0.05).
FIG 4: IAV infection triggers the differential expression of a multitude of molecules involved in antimicrobial defense. The graphs depict the fold change regulation of selected transcripts as determined by microarray analysis of WT AECII and lungs isolated at the indicated time points post-IAV infection. Data are shown as the mean and the individual results from two independent replicate microarray experiments (2 independent samples; 5 mice per sample) for AECII and three independent replicate microarray experiments for lung tissue (three independent samples). The transcripts listed are grouped into those encoding pathogen recognition receptors (A), factors associated with the IFN I/III response (B), cytokines and chemokines (C), and factors associated with antigen presentation (D). For each bar graph, the dashed horizontal line indicates a fold change of 2.
sensors such as RIG-I specifically in AECII will be essential to shed light on this issue. Nevertheless, the high number of ISG triggered and the correlation between the AECII response and IFN I/III levels in the lung clearly showed that AECII react to their specific microenvironment in vivo. In addition to our findings, cell culture studies have shown that pretreatment of AECII with tumor necrosis factor alpha (TNF-α) and IFN-α greatly enhanced their cytokine and chemokine response to IAV (16). Also, IL-17A and TNF-α synergistically act on CXCL5 expression by AECII in vitro and in vivo (40).

Ultimately, the detailed contributions and interplay of pathogen recognition and the signals provided by the microenvironment remain a central question for our understanding of AECII activation in vivo. Dynamic PRR expression patterns in response to IAV have been observed for AECII (41), and moreover, they respond directly to the virus through various TLR (30, 42). In our study, the exceptionally rapid induction of gene expression changes and the transcriptional upregulation of nucleic acid-sensing PRR in the course of the infection suggested a direct sensing of the virus by AECII also in vivo. Many of the transcripts differentially expressed in AECII are typically triggered by PRR ligation and activation of the NF-κB pathway, and the functional pathway Role of Pattern Recognition Receptors in Recognition of Bacteria and Viruses was the second most significantly overrepresented pathway. Therefore, we propose a model in which the rapid and versatile in vivo AECII response following IAV infection is

FIG 5 The kinetics of cell recruitment and type I/III interferon levels correlate with AECII transcriptional profiles. WT mice were sacrificed at the indicated time points post-IAV infection. Bronchoalveolar lavage (BAL) fluid cells were counted (A), and the macrophage and polymorphonuclear cell (PMN) populations (B) were assessed by flow cytometry. Cell populations were analyzed by gating on macrophages (F4/80+ cells) within all acquired cells and gating on PMN (Gr-1+/CD11b+) within the F4/80− cell fraction. (C) Cell numbers were calculated from the absolute cell count and percent population for all analyzed individual mice. Data from individual mice and the mean per group are shown. (D) The concentration of bioactive type I IFN in BAL fluid was assessed using IFN I/III-sensitive reporter cells and an IFN-β standard. Data are shown as means ± standard errors of the means or as individual mice and mean per group. All data are compiled from n ≥ 5 mice out of at least two independent experiments. Groups were compared by unpaired, two-sided t test (P values: *, <0.05; **, <0.005; ***, <0.001).
Cell suspensions were filtered, and crude cell suspensions from 650 Kunitz units of bovine DNase I (Sigma-Aldrich) and anti-CD16/32 were incubated for 10 min in Dulbecco’s Modified Eagle Medium (DMEM) (Gibco, Life Technologies) supplemented with tissue was disintegrated and incubated for 45 min. The caseinolytic units/100 ml; BD Biosciences) followed by 1% low-melting.

triggered by PRR ligation as well as soluble mediators (Fig. 6). Our results show that the in vivo AECII response aims at the inhibition of viral replication and the recruitment and activation of effector cells. Furthermore, we highlight the need to study AECII within their microenvironment to fully characterize their response to pathogens and their role in the local immune system.

MATERIALS AND METHODS

Mice. C57BL/6 mice were purchased from Harlan, and TLR7ko mice (43) (provided by S. Bauer) were bred at the Helmholtz Centre for Infection Research. Eight- to 12-week-old mice were used. Control groups were age and sex matched. All animal experimental procedures were approved by the local government agency (Nds. Landesamt für Verbraucherschutz und Lebensmittelsicherheit, file no. 33.9-42502-04-11/0443).

Influenza A virus infection. Madin-Darby canine kidney (MDCK) cell-derived IAV PR8/A/34(H1N1) was obtained as described previously (19). Following intraperitoneal injection of ketamine-xylazine, mice were intranasally infected with 101.8 50% tissue culture infective doses (19). Following intraperitoneal injection of ketamine-xylazine, mice were intranasally infected with 101.8 50% tissue culture infective doses (19). Following intraperitoneal injection of ketamine-xylazine, mice were intranasally infected with 101.8 50% tissue culture infective doses (19). Following intraperitoneal injection of ketamine-xylazine, mice were intranasally infected with 101.8 50% tissue culture infective doses (19).

AECII isolation. AECII isolation was performed as described previously (9, 18). Briefly, lungs were perfused and instilled with dispase (5,000 caseinolytic units/100 ml; BD Biosciences) followed by 1% low-melting-point agarose. Excised lungs were incubated in dispase for 45 min. The tissue was disintegrated and incubated for 10 min in Dulbecco’s Modified Eagle Medium (DMEM) (Gibco, Life Technologies) supplemented with 650 Kunitz units of bovine DNase I (Sigma-Aldrich) and anti-CD16/32 (2.4G2). Cell suspensions were filtered, and crude cell suspensions from separate mice were pooled. Cells were stained using antibodies for CD16/32 (clone 93), F4/80 (BM8), CD11b (M1/70), CD11c (N418), CD19 (1D3), and CD45 (30-F11). AECII were isolated by sorting for granular sideward scatter high cells negative for the antibody staining using a BD FACSAria instrument.

Expression microarray analysis. RNA was isolated from 1 × 106 AECII/sample. For lung tissue, lungs were perfused with PBS, excised, homogenized in RLT buffer (Qiagen), and centrifuged. RNA was isolated from the supernatant using the RNeasy minikit (Qiagen). DNA was digested using the RNase-free DNase set (Qiagen). RNA integrity was tested using the Agilent 2100 Bioanalyzer (Agilent Technologies) with the RNA 6000 Nano/Pico kit (Agilent Technologies). Synthesis and fragmentation of labeled cRNA were performed using the GeneChip 3’ IVT Express kit (Affymetrix). For AECII, two independent microarray experiments were conducted for each condition and the material for each independent experiment was pooled from five infected animals. For lung tissue, three independent microarrays were performed for each condition and each array represents an independent animal. All samples were hybridized to GeneChip Mouse Genome 430 2.0 microarrays (Affymetrix) and stained according to the manufacturer’s recommendations. Microarrays were scanned with an Affymetrix GCS 3000 scanner running with GCOS v1.1.1 software. Every analyzed gene is represented by 16 independent probe pairs which establish the basis for the statistical evaluation. Therefore, only reproducibly regulated genes are included in the analysis.

Data analysis. Microarray data were analyzed using GeneSpring GX (Agilent Technologies). The data were summarized, log transformed, and normalized with the Robust Multi-array Analysis (RMA) algorithm. To exclude probe sets with consistently low signal intensities in all microarrays performed, only probe sets with signal intensities above the 20th percentile in at least one of all the performed microarrays were retained. The signal intensities of the replicate arrays from lungs and AECII were averaged, and fold changes were calculated in reference to respective uninfected lung/AECII controls. With respect to the analyzed sample material, in total 8 comparative conditions were considered for fold change calculation, i.e., [IAV-WT-lung-d3] versus [PBS-WT-lung-d0], [IAV-TLR7ko-lung-d3] versus [PBS-TLR7ko-lung-d0], [IAV-WT-AECII-d1] versus [PBS-WT-AECII-d0], [IAV-WT-AECII-d2] versus [PBS-WT-AECII-d0], [IAV-WT-AECII-d1] versus [PBS-TLR7ko-AECII-d0], [IAV-TLR7ko-AECII-d2] versus [PBS-TLR7ko-AECII-d0], and [IAV-TLR7ko-AECII-d1] versus [PBS-TLR7ko-AECII-d0]. Depending on the type of the biological question, only certain combinations of the 8 comparative conditions were considered, i.e., comparison of lungs versus AECII in WT mice; comparison of lungs versus AECII in TLR7ko mice; comparison of WT AECII d1, d2, and d3 versus d0; and comparison of TLR7ko AECII d1, d2, and d3 versus d0. In each analysis, a fold change of >±2 in at least one out of the regarded conditions was considered indicative for a gene to be up- or downregulated. Fold change calculation considering all 8 comparative conditions results in 1,815 regulated probe sets. Signal intensities of regulated genes were further analyzed by k-means clustering, using the individual microarray replicates and using the Genesis software 1.7.3 (44) following Z score transformation (45). Gene Ontology and pathway analysis was performed with Qiagen’s Ingenuity pathway analysis tool (Ingenuity Systems).

Detection of IFN I/III in bronchoalveolar lavage (BAL) fluid. Lungs were flushed with 1 ml saline through the trachea, and samples were spun at 10,000 × g. To determine the amount of IFN I/III, IFN-sensitive epithelial cells from Mx2-Luc reporter mice were treated with the supernatant as described previously (46). A standard curve for the calculation of IFN concentrations was obtained by treating cells with serial dilutions of IFN-β.

Flow cytometric analysis. Cells were collected from BAL fluid, were incubated with a CD16/CD36 (2.4G2) antibody, and stained for CD11b (M1/70), Gr-1 (RB6-8C5), and F4/80 (BM8). Data were acquired using a BD LSRFortessa cell analyzer and analyzed using FlowJo (Tree Star).
Microarray data accession number. Microarray data were deposited in NCBI’s Gene Expression Omnibus and are accessible through the GEO series accession number GSE57008.

SUPPLEMENTAL MATERIAL
Supplemental material for this article may be found at http://mbio.asm.org/lookup/suppl/doi:10.1128/mBio.00276-16/-/DCSupplemental.

ACKNOWLEDGMENTS
This work was supported by the German Research Foundation (BR2221/1-1 to D. Bruder and GU769/5-1 to M. Gunzer) and the Helmholtz Association (HGF) (President’s Initiative and Networking Fund W2/W3-029 to D. Bruder). We thank S. Akira (Osaka University) for permission to obtain TLR7ko mice; L. Gröbe and M. Höxter (Helmholtz Centre for Infection Research) for cell sorting; and P. Hagendorff, S. Kaser, S. Prettin, T. Hirsch, and M. Grashoff (Helmholtz Centre for Infection Research) and F. Ewert (Otto-von-Guericke University Magdeburg) for technical assistance.

FUNDING INFORMATION
This work, including the efforts of Dunja Bruder and Matthias Gunzer, was funded by Deutsche Forschungsgemeinschaft (DFG) (BR2221/1-1 to D. Bruder and GU769/5-1 to M. Gunzer) and the Helmholtz Association (HGF) (President’s Initiative and Networking Fund W2/W3-029 to D. Bruder).

REFERENCES
1. Iwasaki A, Pillai PS. 2014. Innate immunity to influenza virus infection. Nat Rev Immunol 14:315–328. http://dx.doi.org/10.1038/nri3665.
2. Kato H, Sato T, Yoneyama M, Yamamoto M, Uematsu S, Matsui K, Tsujimura T, Takeda K, Fujita T, Takeuchi O, Akira S. 2005. Cell type-specific involvement of RIG-I in antiviral response. Immunity 23:19–28. http://dx.doi.org/10.1016/j.immuni.2005.04.010.
3. Kato H, Takeuchi O, Sato S, Yoneyama M, Yamamoto M, Matsui K, Uematsu S, Jung A, Kawai T, Ishii KJ, Yamaguchi O, Otsu K, Tsujimura T, Koh CS, Reis e Sousa C, Matsuura Y, Fujita T, Akira S. 2006. Differential roles of MDA5 and RIG-I helicases in the recognition of RNA viruses. Nature 441:101–105. http://dx.doi.org/10.1038/nature04734.
4. Mordstein M, Kochs G, Dumoutier L, Koh CS, Reis e Sousa C, Matsuura Y, Fujita T, Takeuchi O, Akira S. 2006. Interferon-λ contributes to the rapid progression but not to the overall fatal outcome of secondary pneumococcal disease following influenza A virus infection. J Innate Immun 5:84–96. http://dx.doi.org/10.1007/s11455-011-0115-4.
5. Katsoulidas E, Carayol N, Woodward J, Konieczna I, Majchrzak-Kita B, Behar SM, Debbabi H, Ghosh S, Kamath AB, Alt J, Demello DE, Dunsmore S, Bader SR, Gruber AD, Akira S, Weiss S, Henriques-Normark B, Bruder D, Gunzer M. 2013. TLR7 contributes to the rapid progression but not to the overall fatal outcome of secondary pneumococcal disease following influenza A virus infection. J Innate Immun 5:84–96. http://dx.doi.org/10.1007/s11455-011-0115-4.
6. Weichiner V, Becher A, Tönness M, Holland G, Knepper J, Bauer T, Gereke M, Autengruber A, Gröbe L, Jeron A, Bruder D, Stegemann-Koniszewski S. 2015. Alveolar epithelial cells orchestrate DC function in murine viral pneumonia. J Clin Invest 122:3652–3664. http://dx.doi.org/10.1172/JCI62139.
7. Crotta S, Davidson S, Mahlakoiv T, Desmet CJ, Buckwalter MR, Albert ML, Staeheli P, Wack A, Carayol N, Woodard J, Konieczna I, Majchrzak-Kita B, Behar SM, Debbabi H, Ghosh S, Kamath AB, Alt J, Demello DE, Dunsmore S, Bader SR, Gruber AD, Akira S, Weiss S, Henriques-Normark B, Bruder D, Gunzer M. 2013. TLR7 contributes to the rapid progression but not to the overall fatal outcome of secondary pneumococcal disease following influenza A virus infection. J Innate Immun 5:84–96. http://dx.doi.org/10.1007/s11455-011-0115-4.
8. Katsoulidas E, Carayol N, Woodward J, Konieczna I, Majchrzak-Kita B, Behar SM, Debbabi H, Ghosh S, Kamath AB, Alt J, Demello DE, Dunsmore S, Bader SR, Gruber AD, Akira S, Weiss S, Henriques-Normark B, Bruder D, Gunzer M. 2013. TLR7 contributes to the rapid progression but not to the overall fatal outcome of secondary pneumococcal disease following influenza A virus infection. J Innate Immun 5:84–96. http://dx.doi.org/10.1007/s11455-011-0115-4.
9. Crotta S, Davidson S, Mahlakoiv T, Desmet CJ, Buckwalter MR, Albert ML, Staeheli P, Wack A, Carayol N, Woodard J, Konieczna I, Majchrzak-Kita B, Behar SM, Debbabi H, Ghosh S, Kamath AB, Alt J, Demello DE, Dunsmore S, Bader SR, Gruber AD, Akira S, Weiss S, Henriques-Normark B, Bruder D, Gunzer M. 2013. TLR7 contributes to the rapid progression but not to the overall fatal outcome of secondary pneumococcal disease following influenza A virus infection. J Innate Immun 5:84–96. http://dx.doi.org/10.1007/s11455-011-0115-4.
10. Gereke M, Jung S, Buer J, Bruder D. 2009. Alveolar epithelial cells orchestrate DC function in murine viral pneumonia. J Clin Invest 119:1317–1328. http://dx.doi.org/10.1172/JCI62139.
27. Everitt AR, Clare S, Pertel T, John SP, Wash RS, Smith SE, Chin CR, Feeley EM, Sims JS, Adams DJ, Wise HM, Kane L, Goulding D, Digard P, Anttila V, Baillie JK, Walsh TS, Hume DA, Palotie A, Xue Y. 2012. IFITM3 restricts the morbidity and mortality associated with influenza. Nature 484:519–523. http://dx.doi.org/10.1038/nature10921.

28. Lenschow DJ, Lai C, Frias-Staheli N, Giannakopoulos NV, Lutz A, Wolff T, Osaki A, Levine B, Schmidt RE, García-Sastré A, Leib DA, Pekosz A, Knobeloeh KP, Horak I, Virgin HW. 2007. IFN-stimulated gene 15 functions as a critical antiviral molecule against influenza, herpes, and Sindbis viruses. Proc Natl Acad Sci USA 104:1371–1376. http://dx.doi.org/10.1073/pnas.0607038104.

29. Nordmann A, Wixler L, Boergeling Y, Wixler V, Ludwig S. 2012. A new splice variant of the human guanylate-binding protein 3 mediates anti-influenza activity through inhibition of viral transcription and replication. FASEB J 26:1290–1300. http://dx.doi.org/10.1096/fj.11-189886.

30. Ioannidis I, Ye F, McNally B, Willette M, Flajo E. 2013. Toll-like receptor expression and induction of type I and type III interferons in primary airway epithelial cells. J Virol 87:3261–3270. http://dx.doi.org/10.1128/JVI.01956-12.

31. Kallfass C, Lienenklaus S, Weiss S, Staeheli P. 2013. Visualizing the beta interferon response in mice during infection with influenza A viruses expressing or lacking nonstructural protein 1. J Virol 87:6925–6930. http://dx.doi.org/10.1128/JVI.00283-13.

32. Jewell NA, Vaghefi N, Mertz SE, Akter P, Peebles RS, Jr, Bakeletz LO, Durbin RK, Flajo E, Durbin JE. 2007. Differential type I interferon induction by respiratory syncytial virus and influenza A virus in vivo. J Virol 81:9790–9800. http://dx.doi.org/10.1128/JVI.01030-07.

33. Diebold SS, Kaiko H, Hemmi H, Akira S, Reis e Sousa C. 2004. Innate antiviral responses by means of TLR7-mediated recognition of single-stranded RNA. Science 303:1529–1531. http://dx.doi.org/10.1126/science.1093616.

34. Culley FJ, Pennycook AM, Tregonning JS, Dodd JS, Wald G, Wells TN, Hulse T, Openshaw PJ. 2006. Role of CXCL5 (RANTES) in viral lung disease. J Exp Med 203:8151–8157. http://dx.doi.org/10.1084/jem.200496-06.

35. Jeyaseelan S, Manzer R, Young SK, Yamamoto M, Akira S, Mason RJ, Worthen GS. 2005. Induction of CXCL5 during inflammation in the rodent lung involves activation of alveolar epithelium. Am J Respir Cell Mol Biol 32:531–539. http://dx.doi.org/10.1165/rcmb.2005-0063OC.

36. Kaminski MM, Ohnemus A, Cornitescu M, Staeheli P. 2012. Plasmacytoid dendritic cells and Toll-like receptor 7-dependent signaling promote efficient protection of mice against highly virulent influenza A virus. J Gen Virol 93:555–559. http://dx.doi.org/10.1099/vir.0.039065-0.

37. Jeisy-Scott V, Davis WG, Patel JR, Bowzard JB, Shieh WJ, Zaki SR, Katz JM, Sambhara S. 2011. Increased MDSC accumulation and Th2 biased response to influenza A virus infection in the absence of TLR7 in mice. PLoS One 6:e25242. http://dx.doi.org/10.1371/journal.pone.0025242.

38. Koyama S, Ishii KJ, Kumar H, Tanimoto T, Coban C, Uematsu S, Kawai T, Akira S. 2007. Differential role of TLR- and RLR-signaling in the immune responses to influenza A virus infection and vaccination. J Immunol 179:4711–4720. http://dx.doi.org/10.4049/jimmunol.179.11.4711.

39. Pang IK, Pillai PS, Iwasaki A. 2013. Efficient influenza A virus replication in the respiratory tract requires signals from TLR7 and RIG-I. Proc Natl Acad Sci USA 110:13910–13915. http://dx.doi.org/10.1073/pnas.1302751110.

40. Liu Y, Mei J, Gonzales L, Yang G, Dai N, Wang P, Zhang P, Favara M, Malcolm KG, Guttentag S, Worthen GS. 2011. IL-17A and TNF-alpha exert synergistic effects on expression of CXCL5 by alveolar type II cells in vivo and in vitro. J Immunol 186:3197–3205. http://dx.doi.org/10.4049/jimmunol.1002016.

41. Hui KP, Lee SM, Cheung CY, Mao H, Lai AK, Chan RW, Chan MC, Tu W, Guan Y, Lau YL, Peiris JS. 2011. H5N1 influenza virus-induced mediators upregulate RIG-I in uninfected cells by paracrine effects contributing to amplified cytokine cascades. J Infect Dis 204:1866–1878. http://dx.doi.org/10.1093/infdis/jir665.

42. Guillot L, Le Goffic R, Bloch S, Esciou N, Akira S, Chignard M, Si-Tahar M. 2005. Involvement of Toll-like receptor 3 in the immune response of lung epithelial cells to double-stranded RNA and influenza A virus. J Biol Chem 280:5571–5580. http://dx.doi.org/10.1074/jbc.M410592200.

43. Hemmi H, Kaisho T, Takeuchi O, Sato S, Sanjo H, Hoshino K, Horiu-chi T, Tomizawa H, Takeda K, Akira S. 2002. Small anti-viral compounds activate immune cells via the TLR7 MyD88-dependent signaling pathway. Nat Immunol 3:196–200. http://dx.doi.org/10.1038/ni758.

44. Sturm A, Quackenbush J, Trajanowski Z. 2002. Genesis: cluster analysis of microarray data. Bioinformatics 18:207–208. http://dx.doi.org/10.1093/bioinformatics/18.1.207.

45. Cheadle C, Vawter MP, Freed WJ, Becker KG. 2003. Analysis of microarray data using Z score transformation. J Mol Diagn 5:73–81. http://dx.doi.org/10.1016/S1525-1578(06)0455-2.

46. Nandakumar R, Finsterbusch K, Lipps C, Neumann B, Grashoff M, Nair S, Hochnadel I, Lienenklaus S, Wappler I, Steinmann E, Hauser H, Pietzschmann T, Kröger A. 2013. Hepatitis C virus replication in mouse cells is restricted by IFN-dependent and -independent mechanisms. Gastroenterology 145:1414–1423. http://dx.doi.org/10.1053/j.gastro.2013.08.037.